CAS: 923978-27-2; (E)-2-(2,6-Dimethyl-4-(3-(4-(Methylthio)Phenyl)-3-Oxoprop-1-En-1-yl)Phenoxy)-2-Methylpropanoic Acid

该化合物是一个合成有机化合物,其结构复杂,包括多种功能组,如苯氧,甲基硫酰胺和一种丙烯酰胺.该化合物可能表现出有机酸的典型特性,包括极地溶剂溶解性以及可能与基地发生反应.甲基硫磺组的存在表明药用化学可能的应用,因为含有硫磺化合物的化合物往往表现出独特的生物活动.该化合物的结构表明它可能与生物目标相互作用,有可能影响与炎症或细胞信号有关的途径.此外,多种甲基组的存在可能会增加脂性,影响其药用和生物利用率.

结构式图片

上下游产品

2-bromo-2-methylpropionic acid 4-(Methylthio)acetophenone ethyl 2-(4-formyl-2,6-dimethylphenoxy)-2-methylpropanoate 4-hydroxy-3,5-dimethylbenzaldehyde

合成工艺路线路线简述

  • 923978-25-0 = 923978-27-2
    反应条件:1.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 2 H,Rt
    标题:Crystalline Form Of Elafibranor
    作者:Szokol,Zsuzsanna
    参考文献:Ip.Com Journal 日期:2018 卷标:18 页码:1-10]

    = 923978-27-2 [标题:Reaction Conditions
    标题:Design,Synthesis,And Biological Evaluation Of Triazolone Derivatives As Potent Pparα/δ Dual Agonists For The Treatment Of Nonalcoholic Steatohepatitis
    作者:Feng,Zhiqi; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2022 卷标:65(3) 页码:2571-2592]

    923978-99-8 + 23877-12-5 = 923978-27-2
    反应条件:1.1 Reagents: Potassium Carbonate Solvents: Acetonitrile; 48 H,80 °C2.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 2 H,Rt
    标题:Crystalline Form Of Elafibranor
    作者:Szokol,Zsuzsanna
    参考文献:Ip.Com Journal 日期:2018 卷标:18 页码:1-10]

    1778-09-2 + 2233-18-3 = 923978-27-2
    反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Methanol; Cooled; 2 H,Rt2.1 Reagents: Potassium Carbonate Solvents: Acetonitrile; 48 H,80 °C3.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 2 H,Rt
    标题:Crystalline Form Of Elafibranor
    作者:Szokol,Zsuzsanna
    参考文献:Ip.Com Journal 日期:2018 卷标:18 页码:1-10
📜Ethyl 2-(4-Formyl-2,6-Dimethylphenoxy)-2-Methylpropanoate置于盐酸,水,Sodium Hydroxide体系中,用 四氢呋喃,甲醇,乙醇 作为反应溶剂,化学反应 6.0H,反应生成 2-[2,6-二甲基-4-[(1E)-3-[4-(甲硫基)苯基]-3-氧代-1-丙烯-1-基]苯氧基]-2-甲基丙酸
参考文献: Solid Forms Of Elafibranor And Processes Thereof[fr] Formes Solides D'élafibranor Et Leurs Procédés
标题: Solid Forms Of Elafibranor And Processes Thereof[fr] Formes Solides D'élafibranor Et Leurs Procédés
摘要:本发明涉及elafibranor的固体形式,其制备方法,Elafibranor的药用盐,它们的晶体和非晶形式以及其制备方法.

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Khan AA, Ul Haq F, Wahab QMF, Aslam T, Khalid A, Ali A. Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments. Cureus. 2025 Feb 24;17(2):e79582. doi: 10.7759/cureus.79582.
2: Gul MH, Waheed A, Wardak AB, Shah Y, Azam Raja HA, Ilmaguook B, Hussaini H, Zafar F. Elafibranor: a breakthrough therapy revolutionizing primary biliary cholangitis (PBC) treatment. Ann Med Surg (Lond). 2025 Jan 31;87(2):454-456. doi: 10.1097/MS9.0000000000002794.
3: Salamat Ali J, Salamat Ali T, Al Hasibuzzaman M. Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis. Ann Med Surg (Lond). 2025 Jan 9;87(1):30-32. doi: 10.1097/MS9.0000000000002868.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知